JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
JMP Securities has maintained a Market Outperform rating on Benitec Biopharma and raised its price target from $16 to $18.
October 14, 2024 | 12:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has maintained a Market Outperform rating on Benitec Biopharma and increased its price target from $16 to $18, indicating positive expectations for the stock.
The increase in price target from $16 to $18 by JMP Securities suggests a positive outlook for Benitec Biopharma. Maintaining a Market Outperform rating indicates confidence in the company's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100